JPH0345793B2 - - Google Patents
Info
- Publication number
- JPH0345793B2 JPH0345793B2 JP58501810A JP50181083A JPH0345793B2 JP H0345793 B2 JPH0345793 B2 JP H0345793B2 JP 58501810 A JP58501810 A JP 58501810A JP 50181083 A JP50181083 A JP 50181083A JP H0345793 B2 JPH0345793 B2 JP H0345793B2
- Authority
- JP
- Japan
- Prior art keywords
- serum
- lipoprotein
- cholesterol
- animal
- lipoproteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 71
- 210000002966 serum Anatomy 0.000 description 69
- 102000004895 Lipoproteins Human genes 0.000 description 38
- 108090001030 Lipoproteins Proteins 0.000 description 38
- 241001465754 Metazoa Species 0.000 description 38
- 235000012000 cholesterol Nutrition 0.000 description 34
- 239000012141 concentrate Substances 0.000 description 31
- 108010010234 HDL Lipoproteins Proteins 0.000 description 30
- 102000015779 HDL Lipoproteins Human genes 0.000 description 30
- 150000002632 lipids Chemical class 0.000 description 20
- 241000283690 Bos taurus Species 0.000 description 15
- 238000003908 quality control method Methods 0.000 description 13
- 238000003556 assay Methods 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 108010007622 LDL Lipoproteins Proteins 0.000 description 10
- 150000003626 triacylglycerols Chemical class 0.000 description 10
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- 101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 description 8
- 102000045903 human LPA Human genes 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 7
- 241000283073 Equus caballus Species 0.000 description 6
- 241000288906 Primates Species 0.000 description 6
- 108010004103 Chylomicrons Proteins 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000012888 bovine serum Substances 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US370324 | 1982-04-20 | ||
| PCT/US1983/000571 WO1983003680A1 (fr) | 1982-04-20 | 1983-04-20 | Procede de production et composition de materiaux de controle de qualite a teneur elevee en lipides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59500582A JPS59500582A (ja) | 1984-04-05 |
| JPH0345793B2 true JPH0345793B2 (fr) | 1991-07-12 |
Family
ID=22175025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50181083A Granted JPS59500582A (ja) | 1982-04-20 | 1983-04-20 | 高められた脂質品質コントロール物質の製造方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59500582A (fr) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4216117A (en) * | 1978-05-15 | 1980-08-05 | Bonderman Dean P | Lipoprotein diluent or solution and method useful in the preparation of assay reference materials |
-
1983
- 1983-04-20 JP JP50181083A patent/JPS59500582A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4216117A (en) * | 1978-05-15 | 1980-08-05 | Bonderman Dean P | Lipoprotein diluent or solution and method useful in the preparation of assay reference materials |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59500582A (ja) | 1984-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4045176A (en) | Preparation of optically clear serum | |
| Peaese | On the structural and functional components of coated vesicles | |
| JP3055933B2 (ja) | 改良された安定な凝固対照 | |
| US3640896A (en) | Process for stabilizing fowl red blood cells | |
| JPH0235260B2 (fr) | ||
| Ryan et al. | Lipid transfer protein from Manducasexta hemolymph | |
| CN107748267A (zh) | 一种测定活化部分凝血活酶时间（aptt）的试剂盒 | |
| DE2258822A1 (de) | Verfahren und mittel zur analyse von isoenzymmustern | |
| US20070135619A1 (en) | Production of a von willebrand factor prepartion having a great specific activity | |
| Ogston et al. | Studies on the heterogeneity of crystallized β-lactoglobulin | |
| NL8402182A (nl) | Humane eiwitten, antiserum en proefuitrustingen. | |
| US6124089A (en) | Blood control and system for erythrocyte sedimentation measurement | |
| Kuypers et al. | The distribution of erythrocyte phospholipids in hereditary spherocytosis demonstrates a minimal role for erythrocyte spectrin on phospholipid diffusion and asymmetry | |
| EP0311094B1 (fr) | Agent diagnostique et procédé pour la détermination de l'apolipoprotéine B | |
| EP0105923A4 (fr) | Procede de production et composition de materiaux de controle de qualite a teneur elevee en lipides. | |
| JPH0345793B2 (fr) | ||
| Proksch et al. | Preparation of optically clear lyophilized human serum for use in preparing control material. | |
| US3764556A (en) | Alcoholic precipitation and 1000x centrifugation preparation of hypercholesterolemic and hypertriglyceridemic sera as lipid determination control | |
| US20210072266A1 (en) | Non-recombinant human insulin-like growth factor binding protein concentrate | |
| Casillas et al. | Chromatographic behaviour of clotting factors | |
| Askonas | Crystallization of goat β-lactoglobulin | |
| US20030080056A1 (en) | Extraction of biological components from body fluids | |
| US3993585A (en) | Elevated human lipids control | |
| US20190018025A1 (en) | Non-recombinant human insulin-like growth factor binding protein concentrate | |
| AT403437B (de) | Physiologisch aktive gewebefaktor-präparation |